2019
DOI: 10.1038/s41419-019-1526-0
|View full text |Cite
|
Sign up to set email alerts
|

Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively

Abstract: The treatment of hyperprolactinemia is based on the use of dopamine agonists, mainly bromocriptine (BRC) and cabergoline (CAB). They reduce tumour size effectively and restore gonadal function. However, there is a difference in drug sensitivity between CAB and BRC in patients with prolactinoma, although the underlying mechanisms are still unknown. Thus, we investigated whether there are differences in tumour sensitivity to CAB and BRC and their possible differential mechanisms in two prolactinoma cell lines. I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
31
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2
1

Relationship

2
7

Authors

Journals

citations
Cited by 31 publications
(35 citation statements)
references
References 33 publications
4
31
0
Order By: Relevance
“…Previous study showed that BRC could inhibit PRL secretion and induce apoptosis in GH3 cells [32,12]. We found that Cur was able to enhance the functions of BRC-induced apoptosis rates in GH3 and MMQ cells.…”
Section: Discussionmentioning
confidence: 60%
“…Previous study showed that BRC could inhibit PRL secretion and induce apoptosis in GH3 cells [32,12]. We found that Cur was able to enhance the functions of BRC-induced apoptosis rates in GH3 and MMQ cells.…”
Section: Discussionmentioning
confidence: 60%
“…Bromocriptine regulates several signaling pathways in tumorigenesis and progression, including the PI3K/AKT and the MAPK/JNK/ERK signaling pathways (4,40). Previous studies have also revealed that STAT proteins are important downstream targets of MAPK and JAK signaling (19,(41)(42)(43).…”
Section: Discussionmentioning
confidence: 99%
“…Patients with prolactinomas usually exhibit symptoms of sexual dysfunction, menstrual disturbance and infertility, and prolactinomas account for ~50% of all patients with pituitary adenomas which are brought to medical attention ( 2 , 3 ). Bromocriptine is generally considered to be the first-choice treatment for patients with prolactinoma ( 4 ). However, at least 30% of patients do not respond to bromocriptine ( 5 ).…”
Section: Introductionmentioning
confidence: 99%
“…This binding alters the downstream signaling in lactotrophs and decreases prolactin secretion [ 17 , 32 ]. Currently, dopamine agonists bromocriptine and cabergoline are the two mainstay treatments for prolactinoma [ 34 ]. They both act as D2 receptor agonists and thus have similar side effects, such as headaches, dizziness, nausea, and vomiting [ 17 ].…”
Section: Prolactin-secreting Pituitary Adenoma (Prolactinomas)mentioning
confidence: 99%